JP2018504444A5 - 医薬組成物 - Google Patents
医薬組成物 Download PDFInfo
- Publication number
- JP2018504444A5 JP2018504444A5 JP2017541780A JP2017541780A JP2018504444A5 JP 2018504444 A5 JP2018504444 A5 JP 2018504444A5 JP 2017541780 A JP2017541780 A JP 2017541780A JP 2017541780 A JP2017541780 A JP 2017541780A JP 2018504444 A5 JP2018504444 A5 JP 2018504444A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical
- composition
- administration
- pharmaceutical composition
- formulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 13
- 239000000203 mixture Substances 0.000 claims 9
- 239000002753 trypsin inhibitor Substances 0.000 claims 7
- 101710006356 ACTI Proteins 0.000 claims 6
- 101700046715 CSTI Proteins 0.000 claims 6
- 101700020566 DEFA4 Proteins 0.000 claims 6
- 101710006353 IP3R Proteins 0.000 claims 6
- 101700035656 ISOTI Proteins 0.000 claims 6
- 101700035039 ITI Proteins 0.000 claims 6
- 101700052013 ITR2 Proteins 0.000 claims 6
- 101700068039 ITRP Proteins 0.000 claims 6
- 101700036939 MTI Proteins 0.000 claims 6
- 101700062451 TI Proteins 0.000 claims 6
- 230000037242 Cmax Effects 0.000 claims 5
- 108090000445 Parathyroid hormone Proteins 0.000 claims 5
- 102000003982 Parathyroid hormone Human genes 0.000 claims 5
- 230000037406 food intake Effects 0.000 claims 5
- 229960001319 parathyroid hormone Drugs 0.000 claims 5
- 239000000199 parathyroid hormone Substances 0.000 claims 5
- 238000010521 absorption reaction Methods 0.000 claims 4
- OGBMKVWORPGQRR-UMXFMPSGSA-N 52232-67-4 Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims 3
- 108010049264 Teriparatide Proteins 0.000 claims 3
- 229960005460 teriparatide Drugs 0.000 claims 3
- 230000035533 AUC Effects 0.000 claims 2
- 235000010469 Glycine max Nutrition 0.000 claims 2
- 240000007842 Glycine max Species 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 108010039627 Aprotinin Proteins 0.000 claims 1
- 235000004418 Durio kutejensis Nutrition 0.000 claims 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N Iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 108010064983 Ovomucin Proteins 0.000 claims 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims 1
- 240000005158 Phaseolus vulgaris Species 0.000 claims 1
- 229960004405 aprotinin Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- UOENJXXSKABLJL-UHFFFAOYSA-M sodium;8-[(2-hydroxybenzoyl)amino]octanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCC([O-])=O UOENJXXSKABLJL-UHFFFAOYSA-M 0.000 claims 1
Claims (14)
- 骨粗鬆症の治療に用いるための医薬組成物であって、治療を必要とする対象に経口摂取により投与するためのものであり、
副甲状腺ホルモンまたはその断片と、
ＳＮＡＣ（８−Ｎ−（２−ヒドロキシベンゾイル）アミノカプリル酸ナトリウム）と
を含む、医薬組成物。 - 前記断片がテリパラチドを含む、請求項１に記載の医薬組成物。
- 少なくとも１つのプロテアーゼ阻害剤をさらに含む、請求項１または２に記載の医薬組成物。
- 前記少なくとも１つのプロテアーゼ阻害剤が、少なくとも１つのトリプシン阻害剤を含む、請求項３に記載の医薬組成物。
- 前記少なくとも１つのトリプシン阻害剤が、ライマメトリプシン阻害剤、アプロチニン、ダイズトリプシン阻害剤およびオボムコイドトリプシン阻害剤からなる群より選択される、請求項４に記載の医薬組成物。
- 前記少なくとも１つのトリプシン阻害剤が、ダイズトリプシン阻害剤を含む、請求項４に記載の医薬組成物。
- ２００〜３０００μｇの範囲内の量の前記副甲状腺ホルモンまたはその断片を含む、請求項１〜６のいずれか一項に記載の医薬組成物。
- １日１回の経口摂取による投与用である、請求項１〜７のいずれか一項に記載の医薬組成物。
- 前記医薬組成物の経口摂取による投与後の前記副甲状腺ホルモンまたはその断片の吸収について、Ｃｍａｘの平均値が３０ｐｇ／ｍｌ〜７００ｐｇ／ｍｌの範囲内となるように処方される、請求項１〜８のいずれか一項に記載の医薬組成物。
- 前記医薬組成物の経口摂取による投与後の前記副甲状腺ホルモンまたはその断片の吸収について、Ｃｍａｘの平均値が５０ｐｇ／ｍｌ〜４５０ｐｇ／ｍｌの範囲内となるように処方される、請求項１〜８のいずれか一項に記載の医薬組成物。
- 前記医薬組成物は、テリパラチドを含み、
前記医薬組成物は、前記医薬組成物の経口摂取による投与後のテリパラチドの吸収について、Ｃｍａｘの平均値が３０ｐｇ／ｍｌ〜３００ｐｇ／ｍｌの範囲内となるように処方される、請求項９に記載の医薬組成物。 - 前記医薬組成物の経口摂取による投与後の前記副甲状腺ホルモンまたはその断片の吸収について、ＡＵＣのＣｍａｘに対する比の平均値が３時間以下となるように処方される、請求項１〜１１のいずれか一項に記載の医薬組成物。
- 前記ＡＵＣのＣｍａｘに対する比の平均値が６０分以下である、請求項１２に記載の医薬組成物。
- 錠剤として処方される、請求項１〜１３のいずれか一項に記載の医薬組成物。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021128281A JP7275207B2 (ja) | 2015-02-09 | 2021-08-04 | 骨粗鬆症の治療 |
| JP2023015960A JP2023055902A (ja) | 2015-02-09 | 2023-02-06 | 骨粗鬆症の治療 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562113619P | 2015-02-09 | 2015-02-09 | |
| US201562113638P | 2015-02-09 | 2015-02-09 | |
| US201562113600P | 2015-02-09 | 2015-02-09 | |
| US201562113625P | 2015-02-09 | 2015-02-09 | |
| US201562113629P | 2015-02-09 | 2015-02-09 | |
| US201562113673P | 2015-02-09 | 2015-02-09 | |
| US201562113604P | 2015-02-09 | 2015-02-09 | |
| US62/113,638 | 2015-02-09 | ||
| US62/113,629 | 2015-02-09 | ||
| US62/113,619 | 2015-02-09 | ||
| US62/113,604 | 2015-02-09 | ||
| US62/113,625 | 2015-02-09 | ||
| US62/113,600 | 2015-02-09 | ||
| US62/113,673 | 2015-02-09 | ||
| PCT/IL2016/050154 WO2016128973A1 (en) | 2015-02-09 | 2016-02-09 | Treatment of osteoporosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021128281A Division JP7275207B2 (ja) | 2015-02-09 | 2021-08-04 | 骨粗鬆症の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504444A JP2018504444A (ja) | 2018-02-15 |
| JP2018504444A5 true JP2018504444A5 (ja) | 2019-03-14 |
| JP6925969B2 JP6925969B2 (ja) | 2021-08-25 |
Family
ID=56614456
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541780A Active JP6925969B2 (ja) | 2015-02-09 | 2016-02-09 | 医薬組成物 |
| JP2017541786A Active JP6925970B2 (ja) | 2015-02-09 | 2016-02-09 | 副甲状腺機能低下症の治療 |
| JP2021128296A Pending JP2021176914A (ja) | 2015-02-09 | 2021-08-04 | 副甲状腺機能低下症の治療 |
| JP2021128281A Active JP7275207B2 (ja) | 2015-02-09 | 2021-08-04 | 骨粗鬆症の治療 |
| JP2023015960A Pending JP2023055902A (ja) | 2015-02-09 | 2023-02-06 | 骨粗鬆症の治療 |
| JP2023078011A Pending JP2023100920A (ja) | 2015-02-09 | 2023-05-10 | 副甲状腺機能低下症の治療 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541786A Active JP6925970B2 (ja) | 2015-02-09 | 2016-02-09 | 副甲状腺機能低下症の治療 |
| JP2021128296A Pending JP2021176914A (ja) | 2015-02-09 | 2021-08-04 | 副甲状腺機能低下症の治療 |
| JP2021128281A Active JP7275207B2 (ja) | 2015-02-09 | 2021-08-04 | 骨粗鬆症の治療 |
| JP2023015960A Pending JP2023055902A (ja) | 2015-02-09 | 2023-02-06 | 骨粗鬆症の治療 |
| JP2023078011A Pending JP2023100920A (ja) | 2015-02-09 | 2023-05-10 | 副甲状腺機能低下症の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (7) | US20180028622A1 (ja) |
| EP (5) | EP3256153A4 (ja) |
| JP (6) | JP6925969B2 (ja) |
| CN (5) | CN107427481A (ja) |
| CA (5) | CA2975578A1 (ja) |
| HK (5) | HK1247823A1 (ja) |
| IL (7) | IL283258B2 (ja) |
| MX (2) | MX2017010220A (ja) |
| WO (5) | WO2016128973A1 (ja) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS56998B1 (sr) | 2010-12-16 | 2018-05-31 | Novo Nordisk As | Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline |
| WO2012140117A1 (en) | 2011-04-12 | 2012-10-18 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| WO2013139694A1 (en) | 2012-03-22 | 2013-09-26 | Novo Nordisk A/S | Compositions of glp-1 peptides and preparation thereof |
| HUE042757T2 (hu) | 2012-03-22 | 2019-07-29 | Novo Nordisk As | Szállító szert tartalmazó készítmények és elõállításuk |
| WO2013189988A1 (en) | 2012-06-20 | 2013-12-27 | Novo Nordisk A/S | Tablet formulation comprising a peptide and a delivery agent |
| CA2975578A1 (en) | 2015-02-09 | 2016-08-18 | Entera Bio Ltd. | Treatment of hypoparathyroidism |
| MX2019001850A (es) * | 2016-08-17 | 2019-05-15 | Entera Bio Ltd | Formulaciones para administracion oral de principios activos. |
| KR102647171B1 (ko) | 2018-02-02 | 2024-03-15 | 노보 노르디스크 에이/에스 | Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물 |
| AU2020342512A1 (en) * | 2019-09-03 | 2022-03-31 | Amgen Inc. | IL-22 oral, intra-rectal, or other gut-related compositions and methods of use thereof |
| CN114306249A (zh) * | 2020-09-28 | 2022-04-12 | 深圳翰宇药业股份有限公司 | 一种特立帕肽冻干药物组合物及其制备方法 |
| CN114288388B (zh) * | 2022-01-25 | 2023-11-03 | 华中科技大学同济医学院附属协和医院 | 网膜素在制备炎症性肠病治疗药物中的应用 |
| WO2023161936A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of growth hormone-releasing hormone |
| WO2023161938A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of kappa opioid receptor agonist peptide |
| WO2023161937A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of glucagon-like peptide-2 |
| WO2023161934A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of active agents |
| WO2023161935A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of growth hormone |
| WO2023161939A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of glucagon-like peptide-1 and analogs thereof |
| WO2023161933A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of parathyroid hormone |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5360793A (en) * | 1993-05-24 | 1994-11-01 | Sterling Winthrop Inc. | Rafting antacid formulation |
| CN1162917A (zh) * | 1994-10-07 | 1997-10-22 | 伯温德药品服务公司 | 肠内涂层组合物，用其涂覆的方法和涂覆制品 |
| CA2220301C (en) * | 1995-06-02 | 2006-02-21 | Alza Corporation | Osmotic device with delayed activation of drug delivery and complete drug release |
| JP3220373B2 (ja) * | 1995-11-28 | 2001-10-22 | バイエル薬品株式会社 | 持続性ニフエジピン製剤 |
| IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
| US6531152B1 (en) | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
| WO2000048589A1 (en) * | 1999-02-22 | 2000-08-24 | Emisphere Holdings, Inc. | Solid oral dosage form containing heparin or a heparinoid in combination with a carrier |
| CA2364849A1 (en) | 1999-02-26 | 2000-08-31 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| ATE288415T1 (de) | 1999-04-05 | 2005-02-15 | Emisphere Tech Inc | Dinatrium-salze, monohydrate und ethanol-solvate |
| US6632451B2 (en) | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
| AU2622301A (en) | 1999-11-05 | 2001-05-14 | Emisphere Technologies, Inc. | Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| KR20020063282A (ko) * | 1999-12-28 | 2002-08-01 | 아지노모토 가부시키가이샤 | 경구 투여용 당뇨병 치료제 |
| HUP0401441A3 (en) * | 2001-08-17 | 2012-09-28 | Novartis Ag | 5-cnac as oral delivery agent for parathyroid hormone fragments |
| BR0214199A (pt) | 2001-11-13 | 2005-01-04 | Emisphere Tech Inc | Composições de fenóxi amina para liberar agentes ativos, forma de unidade de dosagem e método de administração |
| JP5196701B2 (ja) * | 2001-11-29 | 2013-05-15 | エミスフィアー テクノロジーズ インコーポレイテッド | クロモリンナトリウムの経口投与用製剤 |
| US20030198666A1 (en) | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| US20050054557A1 (en) * | 2002-05-09 | 2005-03-10 | Goldberg Michael M. | Compositions for delivering parathyroid hormone and calcitonin |
| TWI307279B (en) * | 2002-08-01 | 2009-03-11 | Novartis Ag | Oral administration of calcitonin |
| JP2007525472A (ja) * | 2003-07-04 | 2007-09-06 | ニコメド ダンマーク エイピーエス | 経口使用のための副甲状腺ホルモン（ｐｔｈ）含有医薬組成物 |
| JP2005281231A (ja) | 2004-03-30 | 2005-10-13 | Bioserentack Co Ltd | 小腸ターゲットタイプの経口ｄｄｓ製剤 |
| US20060052306A1 (en) * | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | GRAS composition for enhanced mucosal delivery of parathyroid hormone |
| US20060078622A1 (en) * | 2004-08-13 | 2006-04-13 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| JP2006111558A (ja) | 2004-10-14 | 2006-04-27 | Bioserentack Co Ltd | 多層構造を有する錠剤状の小腸粘膜付着性経口製剤 |
| WO2006076692A1 (en) * | 2005-01-12 | 2006-07-20 | Emisphere Technologies, Inc. | Compositions for buccal delivery of parathyroid hormone |
| US20080153779A1 (en) | 2005-02-01 | 2008-06-26 | Jun Liao | Gastric Retention and Controlled Release Delivery System |
| US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
| JP5222727B2 (ja) | 2005-09-06 | 2013-06-26 | オーラメッド・ファーマスーティカルズ・インコーポレイテッド | タンパク質を経口投与するための方法及び組成物 |
| KR20140053419A (ko) * | 2005-11-17 | 2014-05-07 | 노파르티스 아게 | 약제학적 조성물 |
| US20070178155A1 (en) * | 2006-01-31 | 2007-08-02 | Jiang David Yihai | Preparation for gastric buoyant sustained drug release dosage form |
| ES2538254T3 (es) | 2006-04-18 | 2015-06-18 | Emisphere Technologies, Inc. | Agentes de administración de dialquil éter |
| JP4642115B2 (ja) * | 2006-12-12 | 2011-03-02 | 株式会社堀場エステック | 流量比率制御装置 |
| WO2008132727A2 (en) * | 2007-04-26 | 2008-11-06 | Technion Research And Development Foundation Ltd | Oral delivery of proteins and peptides |
| US20100285098A1 (en) * | 2007-09-11 | 2010-11-11 | Haley Jeffrey T | Adhering troches with santacid for treatment of throat esophagus and stomach |
| WO2009080764A2 (en) * | 2007-12-20 | 2009-07-02 | Abylnx N.V. | Oral or nasal administration of compounds comprising amino acid sequences |
| IT1393244B1 (it) | 2008-07-18 | 2012-04-12 | Universita' Degli Studi Di Milano | Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale |
| AU2009283821B2 (en) * | 2008-08-18 | 2014-05-29 | Entera Bio Ltd. | Methods and compositions for oral administration of proteins |
| CA2795886A1 (en) * | 2010-04-16 | 2011-10-20 | Novartis Ag | Methods and compositions for improving implant osseointegration |
| RS56998B1 (sr) | 2010-12-16 | 2018-05-31 | Novo Nordisk As | Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline |
| US20130224300A1 (en) | 2011-08-26 | 2013-08-29 | Edward T. Maggio | Compositions and methods thereof for oral administration of drugs |
| US9402877B2 (en) | 2011-11-04 | 2016-08-02 | Xion Pharmaceuticals Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
| WO2013189988A1 (en) | 2012-06-20 | 2013-12-27 | Novo Nordisk A/S | Tablet formulation comprising a peptide and a delivery agent |
| CA2975578A1 (en) | 2015-02-09 | 2016-08-18 | Entera Bio Ltd. | Treatment of hypoparathyroidism |
| MX2019001850A (es) | 2016-08-17 | 2019-05-15 | Entera Bio Ltd | Formulaciones para administracion oral de principios activos. |
-
2016
- 2016-02-09 CA CA2975578A patent/CA2975578A1/en active Pending
- 2016-02-09 WO PCT/IL2016/050154 patent/WO2016128973A1/en active Application Filing
- 2016-02-09 EP EP16748833.7A patent/EP3256153A4/en active Pending
- 2016-02-09 US US15/549,425 patent/US20180028622A1/en active Pending
- 2016-02-09 EP EP16748831.1A patent/EP3256113A4/en active Pending
- 2016-02-09 EP EP16748835.2A patent/EP3256149A4/en active Pending
- 2016-02-09 JP JP2017541780A patent/JP6925969B2/ja active Active
- 2016-02-09 CN CN201680016126.5A patent/CN107427481A/zh active Pending
- 2016-02-09 US US15/549,394 patent/US20180036382A1/en active Pending
- 2016-02-09 WO PCT/IL2016/050153 patent/WO2016128972A1/en active Application Filing
- 2016-02-09 WO PCT/IL2016/050155 patent/WO2016128974A1/en active Application Filing
- 2016-02-09 CA CA2975676A patent/CA2975676A1/en active Pending
- 2016-02-09 CN CN202111014634.9A patent/CN113730556A/zh active Pending
- 2016-02-09 US US15/549,436 patent/US10583177B2/en active Active
- 2016-02-09 EP EP16748834.5A patent/EP3256114A4/en active Pending
- 2016-02-09 CA CA3011654A patent/CA3011654A1/en active Pending
- 2016-02-09 IL IL283258A patent/IL283258B2/en unknown
- 2016-02-09 WO PCT/IL2016/050152 patent/WO2016128971A1/en active Application Filing
- 2016-02-09 MX MX2017010220A patent/MX2017010220A/es unknown
- 2016-02-09 CA CA2975710A patent/CA2975710C/en active Active
- 2016-02-09 JP JP2017541786A patent/JP6925970B2/ja active Active
- 2016-02-09 IL IL253802A patent/IL253802B/en unknown
- 2016-02-09 IL IL303216A patent/IL303216A/en unknown
- 2016-02-09 US US15/549,418 patent/US20180036234A1/en active Pending
- 2016-02-09 CN CN202111014352.9A patent/CN113713090B/zh active Active
- 2016-02-09 CA CA3011657A patent/CA3011657A1/en active Pending
- 2016-02-09 CN CN202111014609.0A patent/CN113694190B/zh active Active
- 2016-02-09 EP EP16748832.9A patent/EP3256152A4/en active Pending
- 2016-02-09 US US15/549,442 patent/US20180050096A1/en not_active Abandoned
- 2016-02-09 CN CN202210601969.9A patent/CN114949185A/zh active Pending
- 2016-02-09 IL IL292417A patent/IL292417A/en unknown
- 2016-02-09 WO PCT/IL2016/050151 patent/WO2016128970A1/en active Application Filing
- 2016-02-09 IL IL292218A patent/IL292218B1/en unknown
-
2017
- 2017-08-02 IL IL253804A patent/IL253804B/en unknown
- 2017-08-02 IL IL253803A patent/IL253803B/en active IP Right Grant
- 2017-08-08 MX MX2022014313A patent/MX2022014313A/es unknown
-
2018
- 2018-06-04 HK HK18107251.9A patent/HK1247823A1/zh unknown
- 2018-06-04 HK HK18107250.0A patent/HK1247822A1/zh unknown
- 2018-06-06 HK HK18107355.4A patent/HK1247835A1/zh unknown
- 2018-06-06 HK HK18107372.3A patent/HK1247838A1/zh unknown
- 2018-06-07 HK HK18107403.6A patent/HK1247843A1/zh unknown
-
2019
- 2019-12-23 US US16/724,400 patent/US20200138913A1/en active Pending
-
2021
- 2021-08-04 JP JP2021128296A patent/JP2021176914A/ja active Pending
- 2021-08-04 JP JP2021128281A patent/JP7275207B2/ja active Active
-
2023
- 2023-02-06 JP JP2023015960A patent/JP2023055902A/ja active Pending
- 2023-05-10 JP JP2023078011A patent/JP2023100920A/ja active Pending
-
2024
- 2024-02-05 US US18/432,185 patent/US20240181020A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504444A5 (ja) | 医薬組成物 | |
| JP2018504445A5 (ja) | ||
| MX2022014313A (es) | Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada. | |
| RU2015147876A (ru) | Пероральная дозированная форма соединений глюкагоноподобного пептида-1 | |
| JP2010133020A5 (ja) | 導電性酸窒化物を有する電極及びその作製方法 | |
| WO2008063910A3 (en) | Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions | |
| JP2012500254A5 (ja) | ||
| JP2016505613A5 (ja) | ||
| JP2015515459A5 (ja) | ||
| EA202090984A1 (ru) | Диспергируемая в полости рта единица дозирования, содержащая эстетрольный компонент | |
| CA3037257C (en) | Pharmaceutical compositions comprising beclomethasone dipropionate, and formoterol fumarate dihydrate | |
| HRP20191544T1 (hr) | Farmaceutske kombinacije koje sadrže testosteron i tadalafil u liječenju ženske seksualne disfunkcije | |
| NZ737948A (en) | Orodispersible dosage unit containing an estetrol component | |
| JP2010520246A5 (ja) | ||
| ECSP11010925A (es) | Partículas inhalables que comprenden tiotropio | |
| JP2019528316A5 (ja) | ||
| MX2016014411A (es) | Formulacion liquida que comprende un compuesto neutralizante de gm-csf. | |
| JP2019524836A5 (ja) | ||
| SI2906233T1 (en) | Pharmaceutical forms for the treatment and prevention of obesity | |
| WO2008104852A3 (en) | Pharmaceutical compositions comprising adsorbate of fenofibrate | |
| JP2015522632A5 (ja) | ||
| WO2012020301A3 (en) | Oral controlled release pharmaceutical compositions of blonanserin | |
| WO2020013777A3 (en) | Tablet formulations comprising metformin and sitagliptin | |
| WO2006048261A3 (en) | Oral solid dosage forms containing a low dose of estradiol | |
| EA200601265A1 (ru) | Фармацевтические композиции, содержащие экстракт euphorbia prostrata |